NECTIN4 and neoplasm: By leveraging the specificity of [68Ga]AJ647 for Nectin-4, we demonstrated the ability to dynamically quantify target engagement across a range of preclinical models, bridging critical gaps in current ADC development strategies and enabling a deeper understanding of drug-tumor interactions.